The mammalian cell banking market size has grown rapidly in recent years. It will grow from $3.14 billion in 2025 to $3.5 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to monoclonal antibody development, vaccine manufacturing growth, regulatory quality requirements, academic research expansion, biologics commercialization.
The mammalian cell banking market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to gene therapy advancements, personalized medicine growth, biosimilar development, cell-based therapy pipelines, long-term cell traceability needs. Major trends in the forecast period include standardization of cell line preservation, growth of biopharmaceutical pipelines, expansion of CGMP-compliant cell banks, increased focus on genetic stability, rising outsourcing to specialized facilities.
The growing demand for cell-based therapies is expected to significantly drive the expansion of the mammalian cell banking market. Cell-based therapies involve advanced treatments using living, often modified or engineered, cells to repair, replace, or regenerate damaged tissues and organs, offering targeted solutions for various diseases. As chronic and rare diseases become more prevalent, there is an increasing need for more effective and precise treatments. Mammalian cell banking plays a key role in supporting these therapies by providing a consistent, high-quality cell source, ensuring safety, scalability, and reliability in the development and production of regenerative treatments. For example, the American Society of Gene and Cell Therapy reported in April 2024 that the number of therapies in clinical pipelines has grown, with Phase I trials showing the strongest growth of 11% since late 2022. This surge in demand for cell-based therapies is therefore fueling the growth of the mammalian cell banking market.
Companies in the mammalian cell banking market are advancing the field by developing innovative stable cell line systems that improve cell line productivity, ensure long-term genetic stability, and streamline biopharmaceutical manufacturing. Stable cell line systems are engineered mammalian cells that can consistently produce specific proteins or therapeutic molecules across generations with high genetic stability. For example, WuXi Biologics, a biopharmaceutical company based in China, introduced the WuXia293 Stable platform in August 2024. This HEK293-based stable cell line system is designed for the development and production of challenging biologic molecules. By using proprietary cell line development technology, the platform ensures stable expression, consistent quality, and scalable production, overcoming challenges typically seen with traditional CHO cell systems, such as low yields and compromised quality. The WuXia293 Stable platform provides higher protein yields, better human-like glycosylation, and more efficient production for clinical and commercial use.
In April 2025, Sartorius, a Germany-based life sciences technology provider, formed a strategic CDMO collaboration with Mabion S.A. to support comprehensive biopharmaceutical development using mammalian cell systems. This partnership enables Sartorius to enhance its capabilities in mammalian cell banking by combining advanced cell line development, upstream process optimization, and proprietary cell culture media with Mabion’s GMP-compliant process development, scale-up, and large-scale biologics manufacturing. Mabion is a Poland-based biopharmaceutical CDMO focused on mammalian cell culture-based protein production and GMP manufacturing of both drug substances and drug products.
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences.
North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mammalian cell banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the mammalian cell banking market by raising costs for cryogenic equipment, storage systems, and specialized consumables sourced internationally. Biopharmaceutical production hubs in North America, Europe, and Asia-Pacific are most affected, particularly master and working cell bank segments. On the positive side, tariffs are driving domestic manufacturing investments, improved supply chain security, and regional cell banking infrastructure development.
The mammalian cell banking market research report is one of a series of new reports that provides mammalian cell banking market statistics, including mammalian cell banking industry global market size, regional shares, competitors with a mammalian cell banking market share, detailed mammalian cell banking market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell banking industry. This mammalian cell banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Mammalian cell banking is the organized procedure of producing, preserving, and storing well-characterized mammalian cell stocks under strict conditions, typically at very low temperatures, to ensure their long-term survival, genetic consistency, and functional performance. This method maintains the cells’ uniformity, prevents contamination, and preserves their original traits over time, providing a reliable and standardized resource for future use.
The primary types of products in mammalian cell banking are master cell bank and working cell bank. A master cell bank (MCB) is a carefully prepared and extensively characterized collection of cells stored in multiple vials under controlled cryogenic conditions. It includes various cell types such as Chinese hamster ovary (CHO), baby hamster kidney (BHK), non-secreting 0 (NS0), YB2/0 and P2/0, human embryonic kidney 293 (HEK293) and derivatives, and HeLa cells. Storage methods include liquid nitrogen, controlled-rate freezing, and flash freezing. Master cell banks are used in drug development, vaccine production, gene therapy, and monoclonal antibody production, serving end users such as academic and research laboratories, biopharmaceutical companies, and contract research organizations (CROs).
The mammalian cell banking market consists of sales of cryopreservation media, cell culture reagents, storage vials, cryogenic storage equipment, and quality control kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The mammalian cell banking market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to gene therapy advancements, personalized medicine growth, biosimilar development, cell-based therapy pipelines, long-term cell traceability needs. Major trends in the forecast period include standardization of cell line preservation, growth of biopharmaceutical pipelines, expansion of CGMP-compliant cell banks, increased focus on genetic stability, rising outsourcing to specialized facilities.
The growing demand for cell-based therapies is expected to significantly drive the expansion of the mammalian cell banking market. Cell-based therapies involve advanced treatments using living, often modified or engineered, cells to repair, replace, or regenerate damaged tissues and organs, offering targeted solutions for various diseases. As chronic and rare diseases become more prevalent, there is an increasing need for more effective and precise treatments. Mammalian cell banking plays a key role in supporting these therapies by providing a consistent, high-quality cell source, ensuring safety, scalability, and reliability in the development and production of regenerative treatments. For example, the American Society of Gene and Cell Therapy reported in April 2024 that the number of therapies in clinical pipelines has grown, with Phase I trials showing the strongest growth of 11% since late 2022. This surge in demand for cell-based therapies is therefore fueling the growth of the mammalian cell banking market.
Companies in the mammalian cell banking market are advancing the field by developing innovative stable cell line systems that improve cell line productivity, ensure long-term genetic stability, and streamline biopharmaceutical manufacturing. Stable cell line systems are engineered mammalian cells that can consistently produce specific proteins or therapeutic molecules across generations with high genetic stability. For example, WuXi Biologics, a biopharmaceutical company based in China, introduced the WuXia293 Stable platform in August 2024. This HEK293-based stable cell line system is designed for the development and production of challenging biologic molecules. By using proprietary cell line development technology, the platform ensures stable expression, consistent quality, and scalable production, overcoming challenges typically seen with traditional CHO cell systems, such as low yields and compromised quality. The WuXia293 Stable platform provides higher protein yields, better human-like glycosylation, and more efficient production for clinical and commercial use.
In April 2025, Sartorius, a Germany-based life sciences technology provider, formed a strategic CDMO collaboration with Mabion S.A. to support comprehensive biopharmaceutical development using mammalian cell systems. This partnership enables Sartorius to enhance its capabilities in mammalian cell banking by combining advanced cell line development, upstream process optimization, and proprietary cell culture media with Mabion’s GMP-compliant process development, scale-up, and large-scale biologics manufacturing. Mabion is a Poland-based biopharmaceutical CDMO focused on mammalian cell culture-based protein production and GMP manufacturing of both drug substances and drug products.
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences.
North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mammalian cell banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the mammalian cell banking market by raising costs for cryogenic equipment, storage systems, and specialized consumables sourced internationally. Biopharmaceutical production hubs in North America, Europe, and Asia-Pacific are most affected, particularly master and working cell bank segments. On the positive side, tariffs are driving domestic manufacturing investments, improved supply chain security, and regional cell banking infrastructure development.
The mammalian cell banking market research report is one of a series of new reports that provides mammalian cell banking market statistics, including mammalian cell banking industry global market size, regional shares, competitors with a mammalian cell banking market share, detailed mammalian cell banking market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell banking industry. This mammalian cell banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Mammalian cell banking is the organized procedure of producing, preserving, and storing well-characterized mammalian cell stocks under strict conditions, typically at very low temperatures, to ensure their long-term survival, genetic consistency, and functional performance. This method maintains the cells’ uniformity, prevents contamination, and preserves their original traits over time, providing a reliable and standardized resource for future use.
The primary types of products in mammalian cell banking are master cell bank and working cell bank. A master cell bank (MCB) is a carefully prepared and extensively characterized collection of cells stored in multiple vials under controlled cryogenic conditions. It includes various cell types such as Chinese hamster ovary (CHO), baby hamster kidney (BHK), non-secreting 0 (NS0), YB2/0 and P2/0, human embryonic kidney 293 (HEK293) and derivatives, and HeLa cells. Storage methods include liquid nitrogen, controlled-rate freezing, and flash freezing. Master cell banks are used in drug development, vaccine production, gene therapy, and monoclonal antibody production, serving end users such as academic and research laboratories, biopharmaceutical companies, and contract research organizations (CROs).
The mammalian cell banking market consists of sales of cryopreservation media, cell culture reagents, storage vials, cryogenic storage equipment, and quality control kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Mammalian Cell Banking Market Characteristics
3. Mammalian Cell Banking Market Supply Chain Analysis
4. Global Mammalian Cell Banking Market Trends and Strategies
5. Mammalian Cell Banking Market Analysis of End Use Industries
7. Global Mammalian Cell Banking Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Mammalian Cell Banking Total Addressable Market (TAM) Analysis for the Market
9. Mammalian Cell Banking Market Segmentation
10. Mammalian Cell Banking Market Regional and Country Analysis
11. Asia-Pacific Mammalian Cell Banking Market
12. China Mammalian Cell Banking Market
13. India Mammalian Cell Banking Market
14. Japan Mammalian Cell Banking Market
15. Australia Mammalian Cell Banking Market
16. Indonesia Mammalian Cell Banking Market
17. South Korea Mammalian Cell Banking Market
18. Taiwan Mammalian Cell Banking Market
19. South East Asia Mammalian Cell Banking Market
20. Western Europe Mammalian Cell Banking Market
21. UK Mammalian Cell Banking Market
22. Germany Mammalian Cell Banking Market
23. France Mammalian Cell Banking Market
24. Italy Mammalian Cell Banking Market
25. Spain Mammalian Cell Banking Market
26. Eastern Europe Mammalian Cell Banking Market
27. Russia Mammalian Cell Banking Market
28. North America Mammalian Cell Banking Market
29. USA Mammalian Cell Banking Market
30. Canada Mammalian Cell Banking Market
31. South America Mammalian Cell Banking Market
32. Brazil Mammalian Cell Banking Market
33. Middle East Mammalian Cell Banking Market
34. Africa Mammalian Cell Banking Market
36. Mammalian Cell Banking Market Competitive Landscape and Company Profiles
37. Mammalian Cell Banking Market Other Major and Innovative Companies
40. Mammalian Cell Banking Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Mammalian Cell Banking Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses mammalian cell banking market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for mammalian cell banking? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mammalian cell banking market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Master Cell Bank; Working Cell Bank2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO); Baby Hamster Kidney (BHK); Non-Secreting 0 (NS0); YB2/0 And P2/0; Human Embryonic Kidney 293 (HEK293) And Derivatives; Henrietta Lacks (HELA)
3) By Storage Type: Liquid Nitrogen; Controlled Rate Freezer; Flash Freezing
4) By Application: Drug Development; Vaccine Production; Gene Therapy; Monoclonal Antibody Production
5) By End User: Academic And Research Laboratories; Biopharmaceutical Companies; Contract Research Organizations (CROs)
Subsegments:
1) By Master Cell Bank: Recombinant Cell Lines; Hybridoma Cell Lines; Primary Cell Lines; Genetically Engineered Cell Lines; Viral Vector Producing Cell Lines2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks; Research-Grade Cell Banks; Clinical Trial Cell Banks; Commercial Production Cell Banks; Stability Testing Cell Banks
Companies Mentioned: Merck KGaA; Thermo Fisher Scientific Inc.; Lonza Group AG; Eurofins Scientific SE; Charles River Laboratories International Inc.; Catalent Inc.; Sartorius Stedim Biotech S A; Samsung Biologics Co Ltd; CMIC Holdings Co Ltd; WuXi Biologics Inc.; Evotec SE; AGC Biologics Inc.; GenScript ProBio Co Ltd; Syngene International Limited; KBI Biopharma Inc.; Rentschler Biopharma SE; Polpharma Biologics S A; Abzena plc; 53Biologics; Cellistic; GBI Biomanufacturing; ABL Inc; OmniaBio; uBriGene Biosciences
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Mammalian Cell Banking market report include:- Merck KGaA
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Eurofins Scientific SE
- Charles River Laboratories International Inc.
- Catalent Inc.
- Sartorius Stedim Biotech S A
- Samsung Biologics Co Ltd
- CMIC Holdings Co Ltd
- WuXi Biologics Inc.
- Evotec SE
- AGC Biologics Inc.
- GenScript ProBio Co Ltd
- Syngene International Limited
- KBI Biopharma Inc.
- Rentschler Biopharma SE
- Polpharma Biologics S A
- Abzena plc
- 53Biologics
- Cellistic
- GBI Biomanufacturing
- ABL Inc
- OmniaBio
- uBriGene Biosciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.5 Billion |
| Forecasted Market Value ( USD | $ 5.31 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
